Related Experiment Video
Updated: Sep 19, 2025

05:54
Author Spotlight: Exploring Acupuncture in Alzheimer's Research from Thread-Embedding Techniques to Clinical Trials
Published on: May 10, 2024
1.6K
Equine-Assisted Intervention and Alzheimer's Disease: A Non-randomized, Controlled, Multicenter Study
1University of Tours, Tours, France.
Summary
Equine-assisted intervention (EAI) significantly improved psychological well-being in older adults with Alzheimer disease (AD). EAI reduced behavioral issues and depressive symptoms, enhancing quality of life.
Area of Science:
- Gerontology
- Neuroscience
- Psychology
Background:
- Alzheimer disease (AD) presents significant challenges for older adults, necessitating effective non-pharmacological interventions.
- Existing care models often lack sufficient focus on psychological well-being and environmental enrichment for AD patients.
Purpose of the Study:
- To evaluate the psychological benefits of equine-assisted intervention (EAI) for older adults diagnosed with Alzheimer disease (AD).
- To compare the effects of EAI with adapted physical activity (APA) and a control group (CG) on psychological health outcomes.
Main Methods:
- A multicenter, non-randomized controlled study involving 74 older adults with AD across 14 nursing homes.
- Participants were assigned to an EAI program, an adapted physical activity (APA) program, or a control group (CG).
- Psychological health, including psychobehavioral disorders, quality of life, and depressive symptoms, was assessed at six weeks.
Main Results:
- The EAI group demonstrated a reduction in psychobehavioral disorders by week six.
- Participants in the EAI group reported improved quality of life and a slight decrease in depressive symptoms.
- No significant psychological benefits were observed in the adapted physical activity (APA) or control groups (CG).
Conclusions:
- Equine-assisted intervention (EAI) shows promise as a complementary, non-pharmacological approach for managing Alzheimer disease (AD).
- EAI contributes to environmental enrichment, positively impacting emotional well-being, quality of life, and comfort for individuals with AD in institutional settings.
Related Concept Videos
Alzheimer's Disease: Treatment
265
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
265
Alzheimer's Disease: Overview
686
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
686

